Therefore, negative MLH1 promoter methylation testing is required to proceed with this VUS reassessment approach (Supplementary Table 1, INT2GRATE CRC Code I-IV, and EC Code I-III). The gene discussed is MLH1; the disease is colorectal carcinoma.